Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2

Active, not recruiting

Conditions: Plexiform Neurofibromas (PN)
Neurofibromatosis 1 (NF1)

Interventions: Drug: Selumetinib

First Posted Date: 2015-04-03

Last Posted Date: 2025-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT02407405

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Canagliflozin
Drug: Placebo

First Posted Date: 2015-04-01

Last Posted Date: 2025-03-04

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 67

Registration Number: NCT02404870

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis

Completed

Conditions: Cirrhosis

Interventions: Drug: dual cholate

First Posted Date: 2015-03-27

Last Posted Date: 2025-05-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT02400216

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Phase 2

Active, not recruiting

Conditions: HER2/Neu Negative
Stage IV Breast Cancer AJCC v6 and v7
Progesterone Receptor Negative
Progesterone Receptor Positive

Interventions: Procedure: Computed Tomography
Drug: F-18 16 Alpha-Fluoroestradiol
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2015-03-26

Last Posted Date: 2025-03-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 99

Registration Number: NCT02398773

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 22 locations

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

Phase 2

Terminated

Conditions: Adult Brain Glioblastoma

Interventions: Other: Treatment
Drug: Methoxyamine
Drug: Temozolomide

First Posted Date: 2015-03-24

Last Posted Date: 2019-04-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT02395692

Locations: 🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 9 locations

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Chemotherapy
Procedure: Computed Tomography
Drug: Cytarabine
Other: Fluorothymidine F-18
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2015-03-19

Last Posted Date: 2025-03-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT02392429

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

and more 8 locations

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Phase 1

Recruiting

Conditions: Sarcoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Promyelocytic, Acute
Neurofibroma, Plexiform

Interventions: Drug: TURALIO(R)

First Posted Date: 2015-03-18

Last Posted Date: 2025-06-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT02390752

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

Phase 1

Withdrawn

Conditions: Metastatic Thyroid Cancer

Interventions: Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Anti-Thyroglobulin mTCR PBL

First Posted Date: 2015-03-18

Last Posted Date: 2019-12-16

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02390739

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Phase 1

Active, not recruiting

Conditions: Advanced Bile Duct Carcinoma
Stage IIB Pancreatic Cancer AJCC v6 and v7
Stage II Esophageal Cancer AJCC v7
Stage II Pancreatic Cancer AJCC v6 and v7
Stage IIA Esophageal Cancer AJCC v7
Stage IIA Pancreatic Cancer AJCC v6 and v7
Stage IIB Esophageal Cancer AJCC v7
Stage III Colon Cancer AJCC v7
Stage III Gastric Cancer AJCC v7
Stage III Liver Cancer

Interventions: Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Ropidoxuridine

First Posted Date: 2015-03-06

Last Posted Date: 2025-03-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT02381561

Locations: 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Adavosertib
Drug: Belinostat
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-03-06

Last Posted Date: 2018-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT02381548

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy